McKeithan W, Feyen D, Bruyneel A, Okolotowicz K, Ryan D, Sampson K, et al. Reengineering an Antiarrhythmic Drug Using Patient hiPSC Cardiomyocytes to Improve Therapeutic Potential and Reduce Toxicity. Cell Stem Cell. 2020;27:813-821.e6 pubmed publisher

Carstensen H, Hesselkilde E, Haugaard M, Flethøj M, Carlson J, Pehrson S, et al. Effects of dofetilide and ranolazine on atrial fibrillatory rate in a horse model of acutely induced atrial fibrillation. J Cardiovasc Electrophysiol. 2019;30:596-606 pubmed publisher

McKeithan W, Savchenko A, YU M, Cerignoli F, Bruyneel A, Price J, et al. An Automated Platform for Assessment of Congenital and Drug-Induced Arrhythmia with hiPSC-Derived Cardiomyocytes. Front Physiol. 2017;8:766 pubmed publisher

Carstensen H, Kjær L, Haugaard M, Flethøj M, Hesselkilde E, Kanters J, et al. Antiarrhythmic Effects of Combining Dofetilide and Ranolazine in a Model of Acutely Induced Atrial Fibrillation in Horses. J Cardiovasc Pharmacol. 2018;71:26-35 pubmed publisher

Paul J, Hua S, Ilicic M, Tolosa J, Butler T, Robertson S, et al. Drug delivery to the human and mouse uterus using immunoliposomes targeted to the oxytocin receptor. Am J Obstet Gynecol. 2017;216:283.e1-283.e14 pubmed publisher

Bhave G, Chauder B, Liu W, Dawson E, Kadakia R, Nguyen T, et al. Development of a selective small-molecule inhibitor of Kir1.1, the renal outer medullary potassium channel. Mol Pharmacol. 2011;79:42-50 pubmed publisher